Updated Mar 23, 2026 by Bristol-Myers Squibb
Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.
The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.
Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.
The company has paid down approximately $6 billion of its $10 billion debt reduction target while continuing to prioritize shareholder dividends and share repurchases.
Operational progress includes the successful U.S. launch of Opdivo Qvantig and a pipeline strategy focused on multiple pivotal data readouts for new molecular entities through 2027.
Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.
The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.
Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.
The company has paid down approximately $6 billion of its $10 billion debt reduction target while continuing to prioritize shareholder dividends and share repurchases.
Operational progress includes the successful U.S. launch of Opdivo Qvantig and a pipeline strategy focused on multiple pivotal data readouts for new molecular entities through 2027.